Tertiary Butylhydroquinone vs Blue Dye 2: which is worse?

What is Tertiary Butylhydroquinone?

Tertiary butylhydroquinone (TBHQ) is a synthetic phenolic antioxidant preservative derived from butane. It is one of the most potent antioxidants for polyunsaturated fats and oils and is commonly used in fast-food frying oils. Its chemical formula is C10H14O2.

What is Blue Dye 2?

Blue Dye 2 (Indigotine/Indigo Carmine) is a synthetic disulfonated derivative of indigo. Unlike natural indigo from the indigo plant, the FD&C version is synthetically manufactured from petroleum. It produces a dark royal blue to indigo color and is used in food, pharmaceuticals, and medical diagnostics.

Documented risks

Tertiary Butylhydroquinone: At high doses in animal studies, TBHQ has been shown to cause precancerous stomach lesions (squamous cell hyperplasia) in female rats. A study in Food and Chemical Toxicology documented these dose-dependent precancerous changes. The FDA limits TBHQ to 0.02% of fat content, reflecting dose-dependent safety thresholds. Immune function concerns emerged from research published around 2019-2020. A study (Farouk Musa and colleagues) found that TBHQ impaired the adaptive immune response to influenza in mouse models, including reduced effectiveness of influenza vaccination. EWG highlighted this research in its analysis. These findings have not been confirmed in human clinical trials but raised new dimensions of concern beyond cancer. Neurotoxicity: animal studies have documented TBHQ can cause precursors to certain types of cell injury in neural tissue at high doses, though effects at typical dietary exposure are not established. Allergic reactions including urticaria and contact dermatitis from TBHQ-containing cosmetics and personal care products are documented in dermatology literature. Japan banned TBHQ for food use. The EU restricts it in baby food (completely banned) and in adult food categories with maximum permitted levels. Australia and the UK restrict it.

Blue Dye 2: Animal studies conducted in the 1980s found that high-dose Blue Dye 2 caused brain tumors in male rats. An NTP bioassay (1987) found statistically significant increases in brain gliomas (astrocytomas) in male rats given high doses. The FDA reviewed these findings and determined that the doses far exceeded typical human dietary exposure. Nonetheless, the tumor finding remains in the scientific record as a concerning data point. EFSA's 2010 safety evaluation of Indigo Carmine (E132) reached an unusual conclusion: it could not establish an ADI due to data limitations, including the brain tumor findings. This means EFSA adopted an implicit conservative position — it neither declared Blue 2 safe nor formally banned it, but the absence of an established ADI signals scientific uncertainty. In medical diagnostic use, high intravenous doses of Indigo Carmine can cause hypertension, bradycardia, and in rare cases anaphylaxis. These are dose-specific clinical pharmacological effects, not relevant to dietary consumption at food use levels. Blue 2 was not included in the 2007 Lancet hyperactivity study. Limited direct research links Blue 2 to behavioral effects. The FDA's April 2025 announcement includes Blue 2 in the class of petroleum-based synthetic dyes to be phased out of the US food supply, reflecting updated policy on the category rather than specific new Blue 2 toxicity data.